title: [Predictive value of the assay of serum anti-p25 antibodies in patients with human immunodeficiency virus (HIV-1) infection].
abstract: To assess whether monitoring of antibodies (Ab) directed against the HIV-1 p25 core protein may be used as a predictive marker in the biological monitoring of HIV-infected patients, a study was performed on a transversal cohort of 68 CDC stage II-III, and 36 ARC and 26 AIDS stage IV patients, 37 of whom were being treated with anti-retroviral therapy. A second cohort included 56 patients followed for 3-7 years: 15 stage II-III, 11 ARC and 30 AIDS patients (opportunistic infections: 14; Kaposi's sarcoma: 11; non-Hodgkin's lymphoma: 5). p25 antigenemia and CD4+ blood lymphocyte counts were determined in parallel. Stage II-III patients usually had high and stable anti-p25 Ab levels, ARC patients exhibited more heterogeneous Ab values, while those with AIDS had very low values. No significant difference was observed in the serum anti-p25 levels of patients treated or not with anti-retroviral therapy. In patients whose CD4(+)-cell counts were going to fall below 200/mm3 and/or who were going to progress towards AIDS, the Ab levels started to decrease at a rate of > 1 log U/ml (expressed in arbitrary units/ml) per 5 years at least 2 to 4 years, respectively, before the appearance of the index symptom, despite the fact that the CD4(+)-cell count only differed significantly between progressors and non-progressors one year before the appearance of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: CNRS URA 1463, Groupe Hospitalier Pitié-Salpêtrière, Paris.
authors.forename: E
authors.initials: E
authors.lastname: Fenouillet
authors.forename: N
authors.initials: N
authors.lastname: Blanes
authors.forename: A
authors.initials: A
authors.lastname: Coutellier
authors.forename: J
authors.initials: J
authors.lastname: Demarquest
authors.forename: W
authors.initials: W
authors.lastname: Rozenbaum
authors.forename: J C
authors.initials: JC
authors.lastname: Gluckman
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D015683:Gene Products, gag / Q000276:immunology*; D015483:HIV Antibodies / Q000032:analysis*; D015658:HIV Infections / Q000382:microbiology*; D015497:HIV-1; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011237:Predictive Value of Tests; D011863:Radioimmunoassay; D012189:Retrospective Studies; D013997:Time Factors; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015683:Gene Products, gag; D015483:HIV Antibodies; C059827:HIV gag protein p25; D054301:gag Gene Products, Human Immunodeficiency Virus
vernacular_title: Valeur prédictive du dosage des anticorps anti-p25 sériques chez les sujets infectés par le virus de l'immunodéficience humaine (VIH-1).